ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Clinical and pathologic insights into early and late breast cancer relapses: a real-world analysis from the El Álamo IV registry.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFinding prognostic factors for early and late relapses in operable breast cancer (BC) could improve relapse risk stratification; but there is a lack of real-world data with long enough follow-up.
objectiveTo investigate clinical and pathological features related to early versus late relapses in a real-world cohort of BC patients.
methodsTo identify factors related to early (≤ 2 years) and late (≥ 5 years) relapse in women with stage I-III BC, hormone receptor (HR)-positive and human epidermal growth factor receptor 2-negative (HER2-), and HR-negative (HR -)/HER2 - by immunohistochemistry from El Álamo IV registry, logistic regression model was performed. To explore relapse dynamics, multivariate Cox regression models and annual hazard rates of relapses were reported.
resultsOf the 1493 relapses, early, intermediate, and late relapses represented 28.3%, 29.7%, and 42.1% of all relapses, respectively. In 1050 patients, of both early and late relapses, age > 70 years (odds ratio [OR] 5.13; 95% confidence interval [CI] 3.23-8.15), stage III (OR 3.22; 95% CI 1.90-5.46), histological grade 3 (OR, 2.93; 95% CI 1.69-5.10), and HR - /HER2 - subtype (OR 10.26; 95% CI 6.55-16.05) were associated with an increase of early relapse risk. Annual hazard rate of loco-regional relapses (LRR) steadily increased over time in patients with HR + /HER2 - tumors, while those with HR - /HER2 - tumors exhibited a fluctuating pattern. For distant relapses (DR), the hazard rate peaked at 2 years and then rise steadily in HR + /HER2 - tumors whereas remained variable in HR - /HER2 - tumors. In multivariate Cox model, LRR was associated with stage, subtype, and histological grade, while DR was additionally influenced by age.
conclusionAge at diagnosis, stage, histological grade, and tumor subtype were associated with distinct relapse timing patterns. These findings support further research into relapse dynamics and predictors by analyzing real-world data.
Indexed as
Identifiers
42399549What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.